1,819 reports of this reaction
3.2% of all PANCRELIPASE reports
#2 most reported adverse reaction
DEATH is the #2 most commonly reported adverse reaction for PANCRELIPASE, manufactured by AbbVie Inc.. There are 1,819 FDA adverse event reports linking PANCRELIPASE to DEATH. This represents approximately 3.2% of all 56,891 adverse event reports for this drug.
PANCRELIPASE has an overall safety score of 85 out of 100. Patients taking PANCRELIPASE who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among PANCRELIPASE users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for PANCRELIPASE:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 1,819 FDA reports for PANCRELIPASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 3.2% of all adverse event reports for PANCRELIPASE, making it one of the most commonly reported side effect.
If you experience death while taking PANCRELIPASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.